AU2001289659A1 - Tocotrienolquinone cyclisation product with an anti-hypercholesterol effect - Google Patents

Tocotrienolquinone cyclisation product with an anti-hypercholesterol effect

Info

Publication number
AU2001289659A1
AU2001289659A1 AU2001289659A AU8965901A AU2001289659A1 AU 2001289659 A1 AU2001289659 A1 AU 2001289659A1 AU 2001289659 A AU2001289659 A AU 2001289659A AU 8965901 A AU8965901 A AU 8965901A AU 2001289659 A1 AU2001289659 A1 AU 2001289659A1
Authority
AU
Australia
Prior art keywords
tocotrienolquinone
hypercholesterol
effect
sup
cyclisation product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001289659A
Inventor
Kai-Uwe Baldenius
Klaus Kramer
Karin Schein
Dr. Hartwig Schroder
Rainer Sturmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF SE filed Critical BASF SE
Publication of AU2001289659A1 publication Critical patent/AU2001289659A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Botany (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Furan Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A description is given of the use of at least one compound of the formula I where R<SUP>1</SUP>, R<SUP>2</SUP>, R<SUP>3 </SUP>and R<SUP>4 </SUP>independently of one another are H or C<SUB>1</SUB>-C<SUB>6</SUB>-alkyl; and the use of a compound of the formula I for medical use.
AU2001289659A 2000-07-14 2001-07-13 Tocotrienolquinone cyclisation product with an anti-hypercholesterol effect Abandoned AU2001289659A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10034233 2000-07-14
DE10034233A DE10034233A1 (en) 2000-07-14 2000-07-14 Tocotrienolquinone-cyclization
PCT/EP2001/008163 WO2002006261A1 (en) 2000-07-14 2001-07-13 Tocotrienolquinone cyclisation product with an anti-hypercholesterol effect

Publications (1)

Publication Number Publication Date
AU2001289659A1 true AU2001289659A1 (en) 2002-01-30

Family

ID=7648895

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001289659A Abandoned AU2001289659A1 (en) 2000-07-14 2001-07-13 Tocotrienolquinone cyclisation product with an anti-hypercholesterol effect

Country Status (10)

Country Link
US (1) US6977270B2 (en)
EP (1) EP1301501B1 (en)
JP (1) JP2004504313A (en)
CN (1) CN1441793A (en)
AT (1) ATE263160T1 (en)
AU (1) AU2001289659A1 (en)
DE (2) DE10034233A1 (en)
DK (1) DK1301501T3 (en)
ES (1) ES2218448T3 (en)
WO (1) WO2002006261A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120046237A1 (en) * 1998-04-08 2012-02-23 Theoharides Theoharis C Compositions for protection against superficial vasodilator flush syndrome, and methods of use
PL2471530T3 (en) 2005-06-01 2017-07-31 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
EA021818B1 (en) * 2005-09-15 2015-09-30 Эдисон Фармасьютикалз, Инк. Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and modulation of energy biomarker q10
CA2635280C (en) 2006-02-22 2017-12-12 Edison Pharmaceuticals, Inc. Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
CA2736250C (en) 2008-09-10 2016-12-20 Edison Pharmaceuticals, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
ES2553557T3 (en) * 2008-10-28 2015-12-10 Edison Pharmaceuticals, Inc. Process for the production of alpha-tocotrienol and derivatives
ES2662051T3 (en) 2009-04-28 2018-04-05 Bioelectron Technology Corporation Hereditary optic neuropathy treatment of Leber and dominant optic atrophy with tocotrienol quinones
CA2772294C (en) * 2009-08-26 2018-08-21 Guy M. Miller Methods for the prevention and treatment of cerebral ischemia
US9162957B2 (en) * 2011-07-19 2015-10-20 Edison Pharmaceuticals, Inc. Methods for oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols
KR20150024888A (en) 2012-06-08 2015-03-09 더 오하이오 스테이트 유니버시티 Treating burn and scar injury using tocotrienol
JP7117241B2 (en) 2015-12-16 2022-08-12 ピーティーシー セラピューティクス， インコーポレイテッド Improved methods for enriching alpha-tocotrienols from mixed tocol compositions
JP6905527B2 (en) 2015-12-17 2021-07-21 ピーティーシー セラピューティクス， インコーポレイテッド Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amino 1,4-benzoquinone derivatives for treating oxidative stress disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR910007523A (en) 1989-10-04 1991-05-30 브리스톨-마이어즈 스퀴브 컴페니 Tocotrienols for the treatment of diseases of hypercholesterolemia, hyperlipidemia and thromboembolism
US5217992A (en) 1989-10-04 1993-06-08 Bristol-Myers Squibb Company Tocotrienols in the treatment of hypercholesterolemia, hyperlipidemia and thromboembolic disorders
CA2050514A1 (en) 1990-09-14 1992-03-15 Bradley C. Pearce Acyclic tocotrienol analogs in the treatment of hypercholesterolemia and hyperlipidemia
CA2096496A1 (en) 1992-05-29 1993-11-30 Bradley C. Pearce Acyclic tocotrienol analogs in the treatment of hypercholesterolemia and hyperlipidemia
US5318993A (en) * 1993-04-16 1994-06-07 Bristol-Myers Squibb Company Antihyperlipidemic benzoquinones
EP0669132A1 (en) * 1994-02-23 1995-08-30 van der Kraaij, Antonius Marinus Maria Pharmaceutical composition of vitamin E and acetylsalicylate for treatment and prevention of atherosclerosis
JP3926888B2 (en) 1997-05-27 2007-06-06 株式会社カネカ Cholesterol lowering agent

Also Published As

Publication number Publication date
US20040116715A1 (en) 2004-06-17
CN1441793A (en) 2003-09-10
EP1301501B1 (en) 2004-03-31
DE50101861D1 (en) 2004-05-06
ES2218448T3 (en) 2004-11-16
WO2002006261A1 (en) 2002-01-24
EP1301501A1 (en) 2003-04-16
DE10034233A1 (en) 2002-01-24
US6977270B2 (en) 2005-12-20
DK1301501T3 (en) 2004-07-19
ATE263160T1 (en) 2004-04-15
JP2004504313A (en) 2004-02-12

Similar Documents

Publication Publication Date Title
AU6613896A (en) Chemical compounds
EP1193270A3 (en) Pyrrolobenzodiazepines
AU5485698A (en) Oxyiminopregnancarbolactone
AU7278500A (en) Fungicides
AU2674301A (en) Liquid crystalline medium
BG103310A (en) Benzonaphthyridins as bronchial therapeutical means
AU2001266575A1 (en) Chemical compounds
AU2002249890A1 (en) Carboline derivatives
WO2001055066A3 (en) 3-phenoxy-1-phenyl acetylene derivatives and their use as herbicides
AU2002213421A1 (en) Condensed pyridoindole derivatives
IT1285770B1 (en) CORTICOID COMPOUNDS
AU2001289659A1 (en) Tocotrienolquinone cyclisation product with an anti-hypercholesterol effect
WO2002094020A8 (en) Use of triazolopyrimidine derivatives as microbicides in the protection of materials
EP1295879A4 (en) Medicinal compositions containing propenone derivatives
AU7520898A (en) Tetrahydropyrido compounds
AU2001293707A1 (en) Anti-inflammatory medicament
AU2002213419A1 (en) Condensed pyridoindole derivatives
AU7027100A (en) Novel compounds
AU2001263278A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
AU6339000A (en) Serotonergic benzothiophenes
WO2001009122A3 (en) Serotonergic benzofurans
AU5539899A (en) Novel triazolo(4,5-(d))pyrimidine compounds
AU2881399A (en) N1-modified glycopeptides
AU2002211493A1 (en) Indole derivatives as pde5-inhibitors
AU5390900A (en) Potassium channel blocking agents